Compare KE & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KE | CSTL |
|---|---|---|
| Founded | 1961 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 634.9M | 722.8M |
| IPO Year | 2014 | 2019 |
| Metric | KE | CSTL |
|---|---|---|
| Price | $24.63 | $31.20 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $28.00 | ★ $45.50 |
| AVG Volume (30 Days) | 165.0K | ★ 462.8K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.78 | N/A |
| Revenue | ★ $1,486,727,000.00 | $344,229,000.00 |
| Revenue This Year | N/A | $2.42 |
| Revenue Next Year | $4.57 | $12.69 |
| P/E Ratio | $32.29 | ★ N/A |
| Revenue Growth | N/A | ★ 3.66 |
| 52 Week Low | $21.60 | $17.72 |
| 52 Week High | $33.19 | $44.28 |
| Indicator | KE | CSTL |
|---|---|---|
| Relative Strength Index (RSI) | 45.20 | 70.48 |
| Support Level | $23.56 | $22.88 |
| Resistance Level | $26.95 | $34.97 |
| Average True Range (ATR) | 1.23 | 1.79 |
| MACD | -0.04 | 0.32 |
| Stochastic Oscillator | 48.73 | 81.67 |
Kimball Electronics Inc is a contract electronic manufacturing services company. The company is engaged in producing durable electronics for the automotive, medical, industrial, and public safety end markets. The company's engineering, manufacturing, and supply chain services utilize common production and support capabilities. It is also engaged in producing safety-critical electronic assemblies for its automotive customers. Geographically, it has business units located in the United States, China, Mexico, Poland, Romania, and Thailand. The company derives maximum revenue from Mexico.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.